Odyssey Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
$387 million in cash, cash equivalents and marketable securities as of September 30, 2026, expected to fund operations into the second half of 2028.
$387 million in cash, cash equivalents and marketable securities as of September 30, 2026, expected to fund operations into the second half of 2028.